Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Receivables (2023 - 2025)

Verrica Pharmaceuticals has reported Change in Receivables over the past 3 years, most recently at -$1.8 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$1.8 million for Q4 2025, down 989.05% from a year ago — trailing twelve months through Dec 2025 was $5.2 million (up 224.1% YoY), and the annual figure for FY2025 was $5.2 million, up 224.1%.
  • Change in Receivables for Q4 2025 was -$1.8 million at Verrica Pharmaceuticals, up from -$2.1 million in the prior quarter.
  • Over the last five years, Change in Receivables for VRCA hit a ceiling of $5.6 million in Q1 2025 and a floor of -$10.2 million in Q3 2024.
  • Median Change in Receivables over the past 3 years was $1.5 million (2024), compared with a mean of $487200.0.
  • Biggest five-year swings in Change in Receivables: soared 333.72% in 2024 and later crashed 989.05% in 2025.
  • Verrica Pharmaceuticals' Change in Receivables stood at -$86000.0 in 2023, then skyrocketed by 333.72% to $201000.0 in 2024, then crashed by 989.05% to -$1.8 million in 2025.
  • The last three reported values for Change in Receivables were -$1.8 million (Q4 2025), -$2.1 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.